Exciting Research Highlights from Ardelyx at Digestive Disease Week 2025
WALTHAM, Mass. — Ardelyx, Inc. (Nasdaq: ARDX), a pioneering biopharmaceutical company, has an exciting lineup for the Digestive Disease Week Conference (DDW) happening soon. This event is a significant platform for the latest advancements in gastrointestinal health. Ardelyx is pleased to announce three abstracts that have been accepted for poster presentations, highlighting their commitment to addressing severe medical needs in the gastrointestinal disorder landscape.
Showcasing IBSRELA: Pioneering Treatment for IBS-C
IBSRELA (tenapanor) stands out as an innovative treatment option approved by the U.S. Food and Drug Administration for the management of irritable bowel syndrome with constipation (IBS-C) in adults. With the prevalence of IBS-C affecting countless individuals, the importance of effective treatment options cannot be overstated. At DDW, Ardelyx will present groundbreaking data to further validate the efficacy and safety of IBSRELA.
Overview of Accepted Abstracts
Safety and Tolerability of Tenapanor in Pediatric IBS-C Patients
The first poster presentation focuses on a critical study analyzing the safety and tolerability of tenapanor in pediatric patients suffering from IBS-C. This analysis includes blinded safety data from a Phase 3 study and its open-label extension. Experts Thomas Wallach and colleagues will present this important research, providing insights into how IBSRELA may serve the younger population.
Absence of Tenapanor in Breast Milk: A Vital Study
The second abstract addresses findings from a Phase 1 pharmacokinetic study that looks into whether tenapanor or its major metabolite can be found in the breast milk of healthy lactating women after dosing. This research is particularly relevant for nursing mothers, ensuring safety during treatment with IBSRELA.
IBS-C Symptom Severity and Financial Burden
The third presentation reveals intriguing correlations between patient-reported symptom severity and the financial burdens faced by those dealing with IBS-C. This survey will shed light on the broader implications of IBS-C on patients’ lives, emphasizing the need for effective treatments like IBSRELA.
Product Theater: A New Approach to IBS-C Treatment
In collaboration with DDW, Ardelyx is sponsoring a Product Theater titled “Integrating a Different Mechanism of Action, a Different Class of Therapy, Into the Treatment of Adults with IBS-C.” Scheduled for May 4, this session will feature Dr. Satish Rao and NP Christina Hanson elaborating on essential clinical considerations and patient case studies related to the management of IBS-C in adults. Insights drawn from two Phase 3 clinical trials will showcase the benefits of employing a unique therapeutic approach.
About IBSRELA® (tenapanor)
IBSRELA operates as a locally acting inhibitor of the sodium/hydrogen exchanger 3 (NHE3), which plays a crucial role in sodium absorption across the intestinal lining. By inhibiting NHE3, tenapanor enhances water retention in the intestine, thus promoting softer stool consistency and faster transit times. Furthermore, it has been recognized for its ability to ease abdominal pain by diminishing visceral hypersensitivity and gut permeability in experimental models.
Understanding Irritable Bowel Syndrome with Constipation (IBS-C)
IBS-C is a chronic gastrointestinal disorder impacting millions of individuals. Characterized by abdominal discomfort and irregular bowel movements, it significantly detracts from quality of life, contributing to lost productivity and increased healthcare costs. Acknowledging the profound effects of IBS-C highlights the urgency for continued research and development in this area and the vital role that IBSRELA plays in addressing these challenges.
Important Safety Information
Patient safety remains a top priority at Ardelyx. It’s crucial to note that IBSRELA is contraindicated in children under six years due to the risk of dehydration, and those between six and twelve years should be carefully monitored. Adverse reactions include diarrhea, which was experienced by some patients during studies. Proper monitoring and patient education are essential components of treatment.
About Ardelyx
Founded on a mission to innovate and commercialize first-in-class medicines, Ardelyx, Inc., is leading advancements in gastrointestinal care. With their flagship products, IBSRELA and XPHOZAH, Ardelyx remains dedicated to developing new therapies that address significant healthcare needs. Their collaborations extend across global markets, providing access to effective treatment for various conditions.
Frequently Asked Questions
What is the main focus of Ardelyx at DDW 2025?
Ardelyx will present three research abstracts related to IBSRELA, emphasizing its efficacy and safety in treating IBS-C.
What are the poster presentations about?
The presentations discuss tenapanor's safety in pediatric patients, its absence in breast milk, and the connection between IBS-C symptom severity and financial burdens.
What is IBSRELA and how does it work?
IBSRELA (tenapanor) is a medication that treats IBS-C by inhibiting sodium absorption in the intestine, resulting in quicker transit times and softer stools.
Who should avoid using IBSRELA?
IBSRELA is not recommended for patients under six years due to the risk of dehydration, and caution is advised for those aged six to less than twelve.
How does Ardelyx support its mission in healthcare?
Ardelyx supports healthcare through innovative drug development aimed at addressing significant unmet medical needs, primarily in gastrointestinal disorders.
